recombinant human activated protein C
Recombinant human activated protein C ameliorates oleic acid induced lung injury in awake sheep
... Introduction Acute lung injury (ALI) may arise both after sepsis and non-septic inflammatory conditions and is often associated with the release of fatty acids, including oleic acid (OA). Infusion of OA has been used ...
8
Recombinant human activated protein C: current insights into its mechanism of action
... (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial [26], septic patients who were treated with APC exhibited a significant decrease in D-dimer levels as ...
6
Inhaled aerosolised recombinant human activated protein C ameliorates endotoxin induced lung injury in anaesthetised sheep
... aerosolised recombinant human activated protein C; LPS: lipopolysaccharide; LVSWI: left ventricular stroke work index; MAP: mean systemic arterial pressure; PaCO 2 : partial pressure of ...
9
Drotrecogin alfa (aktiviert) bei der Behandlung der schweren Sepsis Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults
... aktiviertes Protein C, rekombinan- tes aktiviertes Protein C, rhAPC, DAA) ist eine neue The- rapie, deren klinische Effektivität und Kosteneffektivität in diesem HTA-Bericht untersucht werden ...
12
Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock
... Following a baseline (BL) measurement, sheep were randomly allocated to one of three groups (n = 7 each): an uninjured, untreated sham group; an injured, untreated control group; and an injured group treated with rhAPC. ...
12
Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach
... after the large clinical trial PROWESS-SHOCK failed to identify any bene fi cial effect in patients with sepsis. However, in the fi rst place, aPC was approved for use in patients with sepsis because the PROWESS study ...
7
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis – a case control study
... were protein C defi- cient with a mean protein C level of ...baseline protein C level of ...baseline protein C levels of 47 and 50% in the rhAPC group and the ...
8
Recombinant human activated protein C attenuates endotoxin induced lung injury in awake sheep
... of protein C and ...of protein C following administration of rhAPC agrees with corresponding findings of Wang and colleagues in septic sheep treated with rhAPC ...in protein C is ...
13
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C
... Recombinant human activated protein C (rhAPC) has been demonstrated to improve mortality in critically ill patients with septic shock ...
6
Activated protein C ameliorates impaired renal microvascular oxygenation and sodium reabsorption in endotoxemic rats
... After baseline measurements were performed 30 min after Oxyphor G2 infusion, endotoxemic shock was induced in three groups of rats ( n = 8/group) by a bolus of lipopolysaccharide (LPS, 10 mg/kg, serotype 0127:B8, ...
11
Controversial treatment of a victim of severe head injury complicated by septic shock and acute respiratory distress syndrome
... trauma. Recombinant human activated protein C (APC) reportedly improves circulation and respiration in severe sepsis, but is contraindicated after head injury because of increased risk ...
6
Microcirculatory alterations in ischemia–reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition
... the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study in vivo reduced the extent of transient leukocyte–endothelial-cell interactions ...
5
The protein C pathway: implications for the design of the RESPOND study
... plasma protein C level in sepsis has been demonstrated in a number of studies in which depressed protein C levels were associated with increased likelihood of negative ...(Recombinant ...
7
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
... 23. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated ...
6
Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
... prospective recombinant human activated protein C worldwide evaluation in severe sepsis; IRP: improved response polymorphism; DROTAA: drotrecogin alfa (activated); APACHE II: ...
11
Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin
... Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul ...of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated ...
7
Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation
... Recombinant human soluble TM (rTM) comprises the extracellular domain of TM and has been used for treat- ment of DIC since 2008 in Japan ...of recombinant APC was also shown effective in reducing ...
8
Human activated protein C variants in a rat model of arterial thrombosis
... the recombinant hAPC variants with or without protein S (as indicated in the figures) were investigated in rat plasma and in human ...below). Human citrated plasma was acquired from a mix- ...
9
Mitogen-Activated Protein Kinases Regulate LSF Occupancy at the Human Immunodeficiency Virus Type 1 Promoter
... spot C is the chymotryptic phos- phopeptide containing a singly phosphorylated serine residue at either position 289 or 291, and spot B is an alternatively migrating configuration of the singly phosphorylated ...
11
Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation
... the Human Recombinant Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group showed a significant reduction in 28-day mortality and a quicker resolution of organ ...
9